Related Experiment Videos
In vitro antisickling activity of cromolyn sodium
A B Fall1, M Toppet, A Ferster
1Laboratoire de Pharmacognosie et Bromatologie, Institut de Pharmacie de l'Université Libre de Bruxelles, Belgium.
Insights
Cromolyn sodium shows significant antisickling activity in vitro for sickle cell disease (SCD) patients. This suggests it may be a promising therapeutic candidate for further clinical investigation.
Area of Science:
- Hematology
- Pharmacology
Background:
- Sickle cell disease (SCD) is a debilitating genetic blood disorder.
- Current therapies for SCD have limitations, necessitating novel treatment strategies.
Purpose of the Study:
- To investigate the in vitro antisickling activity of cromolyn sodium.
- To compare the efficacy of cromolyn sodium against pentoxifylline, a standard treatment.
Main Methods:
- Blood samples were collected from 15 children with severe SCD.
- The number of sickle cells was quantified under deoxygenated conditions.
- Cromolyn sodium was tested at eight different concentrations.
Main Results:
- Cromolyn sodium demonstrated significantly higher antisickling activity compared to pentoxifylline.
- The effect was observed across all tested concentrations of cromolyn sodium.
Conclusions:
- Cromolyn sodium exhibits potent in vitro antisickling properties.
- It represents a promising therapeutic agent for sickle cell disease.
- Further in vivo studies are warranted to confirm its clinical efficacy.
Abstract:
The improvement in sickle cell disease (SCD) children receiving cromolyn sodium therapy prompted us to investigate its antisickling activity in vitro. The number of sickle cells was determined in deoxygenated blood samples from 15 children with severe SCD. At the eight concentrations tested, cromolyn sodium exhibited a significantly higher activity than pentoxifylline, the standard compound. Therefore cromolyn sodium would appear to be an interesting candidate for SCD therapy and deserves further in vivo investigations.